Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease.

Hiroaki YaoiYasuaki ShidaKenichi OgiwaraTakehisa KitazawaMidori Shima Keiji Nogami

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2022)

Emicizumab promoted mechanisms of thrombus formation in vitro in type 3 and type 1 VWD, suggesting the possibility of alternative therapeutic protocols in these patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
patient reported outcomes